Improving Guideline Development Processes: Integrating Evidence Estimation and Decision-Analytical Frameworks.

Benjamin Djulbegovic, Iztok Hozo, Ilkka Kunnamo, Gordon Guyatt
Author Information
  1. Benjamin Djulbegovic: Department of Medicine, Division of Medical Hematology and Oncology, Medical University of South Carolina, Charleston, South Carolina, USA. ORCID
  2. Iztok Hozo: Department of Mathematics, Indiana University Northwest, Gary, Indiana, USA.
  3. Ilkka Kunnamo: Duodecim Publishing Company, Helsinki, Finland.
  4. Gordon Guyatt: Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.

Abstract

RATIONALE, AIMS AND OBJECTIVES: Despite using state-of-the-art methodologies like Grades of Recommendation, Assessment, Development and Evaluation (GRADE), current guideline development frameworks still rely heavily on panellists' intuitive integration of evidence related to the benefits and harms/burdens of health interventions. This leads to the 'black-box' and 'integration' problems, highlighting the lack of transparency in guideline decision-making. Combined with humans' limited capacity to process the large volumes of information presented in Summary of Findings (SoF) tables-the primary output of systematic reviews that underpin guideline recommendations-this reliance on non-explicit processes raises concerns about the trustworthiness of clinical practice guidelines.
METHODS: SoF tables provide the best available evidence, derived from frequentist or Bayesian estimation frameworks. Decision analysis, which integrates both types of estimates but considers intervention consequences, is the only analytical approach that combines multiple outcomes (benefits, harms and costs) into a single metric to support decision-making. Such analysis seeks to identify the optimal decision by balancing harms, benefits and uncertainties. This paper leverages the PICO format (Population, Intervention, Comparison(s), Outcome) as a conceptual basis for deriving SoF tables. Subsequently, we propose a solution to GRADE's "black-box" and "integration" problems by matching PICO-based SoF with decision models.
RESULTS: We succeeded in connecting the PICO framework to simple decision-analytical models, restricted to time frames supported by empirically verifiable evidence, to calculate which competing intervention offers the greatest benefit (net differences in expected utility; ΔEU). The single metric [ΔEU] enabled a simple, transparent and easy-to-understand assessment of the superiority of competing management strategies across multiple outcomes (considering both benefits and harms), addressing the 'black-box' and 'integration' problems. Completing a SoF-based decision model takes about 10 min. Not surprisingly, the recommendations based on ΔEU may differ from the intuitive recommendations of panels.
CONCLUSION: We propose that incorporating the straightforward and transparent modelling into guideline panels' decision-making processes will enhance their intuitive judgements, resulting in more trustworthy recommendations. Given the simplicity of calculating ΔEU, we advocate for its immediate inclusion in systematic reviews and SoF tables.

Keywords

References

  1. Blood Adv. 2018 Nov 27;2(22):3198-3225 [PMID: 30482763]
  2. J Eval Clin Pract. 2018 Oct;24(5):1232-1239 [PMID: 29314554]
  3. Cancer Control. 2009 Apr;16(2):158-68 [PMID: 19337202]
  4. Psychol Rev. 2022 Jan;129(1):49-72 [PMID: 32658537]
  5. J Eval Clin Pract. 2017 Oct;23(5):915-922 [PMID: 28730671]
  6. BMJ. 2019 Oct 02;367:l5515 [PMID: 31578196]
  7. J Clin Epidemiol. 2020 Mar;119:126-135 [PMID: 31711912]
  8. MedGenMed. 2000 Jan 13;2(1):E6 [PMID: 11104452]
  9. Blood Adv. 2024 Jul 9;8(13):3596-3606 [PMID: 38625997]
  10. JAMA. 2013 Dec 18;310(23):2501-2 [PMID: 24310916]
  11. BMJ Open. 2019 Jun 4;9(6):e027445 [PMID: 31167868]
  12. J Eval Clin Pract. 2023 Apr;29(3):459-471 [PMID: 36694469]
  13. Cancer Treat Res. 2023;189:39-52 [PMID: 37789159]
  14. JAMA. 2019 Aug 27;322(8):725-726 [PMID: 31322650]
  15. Blood Adv. 2019 Dec 10;3(23):3829-3866 [PMID: 31794604]
  16. J Intell. 2018 Apr 25;6(2): [PMID: 31162452]
  17. BMJ. 2008 Apr 26;336(7650):924-6 [PMID: 18436948]
  18. J Eval Clin Pract. 2024 Mar;30(2):281-289 [PMID: 38044860]
  19. Cancer Treat Res. 2023;189:1-24 [PMID: 37789157]
  20. J Eval Clin Pract. 2018 Oct;24(5):1240-1246 [PMID: 30003639]
  21. J Health Econ. 1999 Jun;18(3):341-64 [PMID: 10537899]
  22. BMC Health Serv Res. 2014 Nov 21;14:579 [PMID: 25413154]
  23. J Clin Epidemiol. 2024 Dec;176:111575 [PMID: 39442675]
  24. J Eval Clin Pract. 2019 Apr;25(2):186-195 [PMID: 30575227]
  25. J Eval Clin Pract. 2023 Dec;29(8):1271-1278 [PMID: 37622200]
  26. J Clin Epidemiol. 2013 Feb;66(2):158-72 [PMID: 22609141]
  27. Cancer Treat Res. 2023;189:93-99 [PMID: 37789164]
  28. Blood Adv. 2024 Aug 13;8(15):3914-3916 [PMID: 38759098]
  29. J Clin Epidemiol. 2013 Jul;66(7):726-35 [PMID: 23570745]
  30. Blood Adv. 2023 Nov 28;7(22):7101-7138 [PMID: 37195076]
  31. Lancet. 2017 Jul 22;390(10092):415-423 [PMID: 28215660]
  32. BMJ. 2008 May 10;336(7652):1049-51 [PMID: 18467413]

MeSH Term

Humans
Evidence-Based Medicine
Decision Support Techniques
Practice Guidelines as Topic
Bayes Theorem
Decision Making

Word Cloud

Similar Articles

Cited By